Tracer Shows Promise for Cardiac Amyloidosis Imaging
Washington University in St. Louis researchers report preliminary PET/CT findings for subtyping heart amyloidosis.
Updated on Nov. 18, 2026 in Diseases

Washington University in St. Louis researchers presented preliminary findings on F-18 fluselenamyl, a radiotracer first developed for amyloid imaging in Alzheimer's disease, for use in cardiac amyloidosis. The early evaluation enrolled six patients with a mean age of 66 years.
Why it matters
Telling light chain (AL) amyloidosis apart from transthyretin-mediated amyloidosis (ATTR) is diagnostically difficult, and current imaging has limits for non-invasive subtyping. Because the two subtypes require different treatments, a tracer that can help distinguish them could affect how patients are diagnosed and managed.
The study evaluated six patients, with SUVmax cardiac uptake of 3.5 and 6.5 in the two AL patients and uptake in all three ATTR patients. Because the sample is small and the results are preliminary, the tracer's ability to distinguish AL from ATTR across larger populations remains unknown.
The players
Washington University in St. Louis
A private research university in St. Louis, Missouri, whose researchers led the early evaluation of the F-18 fluselenamyl tracer.
The details
Researchers gave each patient a 60-minute dynamic cardiac F-18 fluselenamyl PET/CT scan followed by a 10-minute static scan at 60 minutes. Myocardial uptake was assessed visually on a five-point scale and quantitatively by SUVmax.
Timeline
Preliminary tracer findings were presented at an RSNA session on November 18, 2026.
Health Landscape
The study takes amyloid PET imaging, developed for Alzheimer's disease, and applies it to the heart, where non-invasive subtyping of cardiac amyloidosis remains an unmet need. If later work confirms the tracer's accuracy, it could extend a imaging approach from neurology into cardiology.
For patients with heart symptoms, a non-invasive scan that could tell amyloidosis subtypes apart might one day spare some people more invasive testing. The tracer is still experimental, so current diagnosis and treatment decisions remain unchanged.
The takeaway
Accurately identifying the type of cardiac amyloidosis matters because treatment depends on it. Patients and clinicians should watch for larger studies before expecting this tracer in routine care.
Further reading
For related coverage of heart conditions, explore more in our Heart Disease section.
Source note: This article includes information reported by AuntMinnie.






